Pharmacological Treatment for Peptic Ulcer Bleeding
10.7704/kjhugr.2018.18.4.231
- Author:
Dae Won MA
1
;
Byung Wook KIM
Author Information
1. Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea. gastro@catholic.ac.kr
- Publication Type:Review
- Keywords:
Peptic ulcer bleeding;
Pharmacological therapy;
Proton pump inhibitor
- MeSH:
Christianity;
Endoscopy;
Gastric Acid;
Hemorrhage;
Humans;
Hydrogen-Ion Concentration;
Infusions, Intravenous;
Mortality;
Peptic Ulcer;
Proton Pump Inhibitors
- From:The Korean Journal of Helicobacter and Upper Gastrointestinal Research
2018;18(4):231-234
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Peptic ulcer bleeding (PUB) is the most common cause of non-variceal upper gastrointestinal bleeding, and its frequency has been declining over the past decades. However, mortality from PUB persists, and it is still a serious challenge in clinical practice. Although endoscopic intervention is the basic treatment modality for PUB, pharmacological therapy is an important adjunct. The emergence of proton pump inhibitors (PPIs) enables maintenance of intragastric pH >6, which greatly helps in the treatment of PUB. Continuous intravenous infusion of high-dose PPI reduces the re-bleeding rate, thereby helping avoid additional surgery in patients with high-risk stigmata. Moreover, administration of PPIs prior to endoscopy may reduce the need for additional endoscopic intervention. Recently introduced gastric acid suppressants, such as potassium-competitive acid blockers, have shown promising results in further treatment of PUB.
